Skip to main content
SURMODICS INC logo

SURMODICS INC — Investor Relations & Filings

Ticker · SRDX ISIN · US8688731004 LEI · 549300H76KXCAAGUS878 US Manufacturing
Open in API
Filings indexed 1,062 across all filing types
Latest filing 2013-02-13 Director's Dealing
Country US United States of America
Listing US SRDX

About SURMODICS INC

https://www.surmodics.com/

Surmodics, Inc. provides performance-enhancing technologies for the healthcare industry, focusing on medical devices and in vitro diagnostics. The company is a leading provider of surface modification technologies, offering customized hydrophilic, hemocompatible, and drug-delivery coatings for intravascular medical devices. In addition to its coatings business, Surmodics develops and commercializes a portfolio of vascular intervention medical devices for the treatment of peripheral arterial and venous disease, including thrombectomy and radial access platforms. The company also offers end-to-end contract development and manufacturing services. Its In Vitro Diagnostics (IVD) division supplies critical chemical components for immunoassays and microarrays, aiming to enhance the sensitivity and reproducibility of diagnostic tests.

Recent filings

Filing Released Lang Actions
FORM 3 SUBMISSION
Director's Dealing
2013-02-13 English
Major Shareholding Notification 2013
Major Shareholding Notification
2013-02-11 English
SC 13G/A Filing
Major Shareholding Notification
2013-02-11 English
FORM 10-Q
Interim / Quarterly Report Q1 2013
2013-02-08 English
Major Shareholding Notification 2013
Major Shareholding Notification
2013-02-07 English
8-K Filing
Capital/Financing Update Classification · 90% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text includes an Item 2.02 Results of Operations and Financial Condition, referencing a press release announcing quarterly results for the period ended December 31, 2012. It also includes Item 8.01 Other Events, specifically announcing a new share repurchase program authorized by the Board of Directors. The document is relatively short (2846 characters) and primarily serves as an announcement of the earnings release and share repurchase program, not the full earnings report itself. The presence of a press release as an exhibit further supports that this is a current report announcing financial results and capital activity. Given the content, the best classification is Capital/Financing Update (CAP) due to the share repurchase program announcement, which is a capital structure change. Although earnings results are mentioned, the document does not contain substantive financial data or analysis itself, so it is not an Earnings Release (ER).
2013-01-30 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.